Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 27 Sep 2026 · Editorial standards

At a glance

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School is the lead sponsor of 90 current clinical trials in our China register. 58 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Rezvilutamide, Abiraterone acetate and Fluorouracil. The most-studied condition is Prostate Cancer.

ClinicalTrials.gov trials by status

Recruiting5864%
Not yet open1618%
Active, closed1112%
By invitation56%

Trials by phase

Observational2932%
Not applicable2022%
Phase 22022%
Phase 1/267%
Phase 356%
Phase EARLY_PHASE144%
Phase 433%
Phase 133%

Clinical trials sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

90 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Food Intake-Related Brain and Metabolic Responses in Obesity NCT07392905 · ClinicalTrials.gov ↗ · Obesity, Brain Function, Metabolomics	Not applicable	Recruiting	2025-12	China
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer NCT07353645 · ClinicalTrials.gov ↗ · Colorectal Cancer, Pancreatic Cancer	Phase 1/2	Recruiting	2026-03	China
Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors NCT05758389 · ClinicalTrials.gov ↗ · Head and Neck Tumors	Phase 2	Recruiting	2022-04	China
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer NCT06305832 · ClinicalTrials.gov ↗ · Prostate Cancer, Biochemical Recurrence Drug: Rezvilutamide	Phase 2	Recruiting	2023-09	China
Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy NCT07711314 · ClinicalTrials.gov ↗ · Prostate Cancer (Post Prostatectomy) Drug: Rezvilutamide	Phase 2	Recruiting	2026-07	China
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma NCT05687357 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal-junction Cancer Drugs: Nab-paclitaxel, Oxaliplatin, Tislelizumab	Phase 2	Recruiting	2023-03	China
The Cognitive Protective Effect of VR-based Cognitive Training in Type 2 Diabetes Patients With Mild Cognitive Impairment NCT07650318 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus (T2DM), Mild Cognitive Impairment (MCI)	Not applicable	Recruiting	2026-06	China
Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD NCT05766449 · ClinicalTrials.gov ↗ · Chronic Hepatitis b, Non-alcoholic Fatty Liver Disease	Observational	Recruiting	2022-06	China
Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer NCT07831993 · ClinicalTrials.gov ↗ · Biliary Tract Cancer Drugs: Cisplatin, Fluorouracil, Gemcitabine	Phase 2	Recruiting	2026-01	China
Ipsilateral Versus Bilateral Systematic Biopsy Combined With MRI/Ultrasound Cognitive Fusion Targeted Biopsy for Prostate Cancer Diagnosis NCT07795723 · ClinicalTrials.gov ↗ · Prostate Cancer	Not applicable	Recruiting	2026-07	China
Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Lifestyle Intervention NCT07630597 · ClinicalTrials.gov ↗ · Obesity & Overweight	Not applicable	Recruiting	2026-05	China
Multicenter, Prospective, Observational Study on the Treatment of Type 2 Diabetes With Proline Plus Empagliflozin Tablets NCT07023172 · ClinicalTrials.gov ↗ · Type 2 Diabetes	Observational	Recruiting	2025-05	China
Efficacy and Olfactory Network of Electro-acupuncture for Subjective Cognitive Decline NCT06758154 · ClinicalTrials.gov ↗ · Subjective Cognitive Decline (SCD)	Not applicable	Recruiting	2024-12	China
Safety and Efficacy of Anricfen for Postoperative Analgesia and Rehabilitation Promotion After Pancreaticoduodenectomy.Intervention Measures: For Normal Adults, Administer Ariceptin Injection Intravenously Post-operation at a Dose of 1 μg/Kgevery 8 Hours for Three Consecutive Days After Surgery. NCT07514637 · ClinicalTrials.gov ↗ · Patients Who Undergo Pancreaticoduodenectomy Drug: Anrikefon	Phase 2	Recruiting	2025-11	China
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer NCT06389760 · ClinicalTrials.gov ↗ · Pancreatic Cancer Drugs: MFOLFIRINOX, Nimotuzumab	Phase 2	Recruiting	2023-10	China
Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC NCT06992232 · ClinicalTrials.gov ↗ · Prostate Cancer Metastatic Disease	Phase 2	Recruiting	2024-08	China
"Real-life" Cohort Study on Patients With Chronic HBV Infection in Jiangsu NCT03097952 · ClinicalTrials.gov ↗ · Hepatitis B， Chronic	Observational	Recruiting	2008-01	China
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer NCT05753566 · ClinicalTrials.gov ↗ · Prostate Cancer, Biochemical Recurrence Drug: Rezvilutamide	Phase 2	Recruiting	2023-03	China
A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer NCT06151262 · ClinicalTrials.gov ↗ · Pancreatic Cancer Drugs: MFOLFIRINOX, Trilaciclib	Phase 2	Recruiting	2024-01	China
Clinical Research Protocol of Ferumoxytol for Magnetic Resonance Enhancement Imaging in Patients With Atherosclerosis. NCT06551805 · ClinicalTrials.gov ↗ · Atherosclerosis	Observational	Recruiting	2024-08	China
Multicenter Validation of a Risk Prediction Model for MDRGNB Infection NCT07603128 · ClinicalTrials.gov ↗ · Infection	Observational	Recruiting	2026-05	China
A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions NCT07532538 · ClinicalTrials.gov ↗ · Hypopharyngeal Cancer, Laryngeal Cancer, Head and Neck Cancer	Observational	Recruiting	2026-04	China
Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer NCT06791148 · ClinicalTrials.gov ↗ · Gastric Cancer Drugs: Albumin-Bound Paclitaxel, Ivonescimab	Phase 2	Recruiting	2024-07	China
The Study of Electrical Acupuncture Stimulation Therapy for Postprostatectomy Incontinence NCT04972669 · ClinicalTrials.gov ↗ · Postprostatectomy Incontinence	Not applicable	Recruiting	2021-03	China
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer NCT05406999 · ClinicalTrials.gov ↗ · Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer Drugs: Abiraterone acetate, Apalutamide, Enzalutamide	Phase 2	Recruiting	2020-02	China
Long-Term Survival After LVAD Implantation in End-Stage Heart Failure NCT07382284 · ClinicalTrials.gov ↗ · End-stage Heart Failure	Observational	Recruiting	2022-07	China
AI-Assisted Remote Insulin Pump Optimization in T1DM NCT07732777 · ClinicalTrials.gov ↗ · Type 1 Diabetes Mellitus, Type 1 Diabetes (T1D)	Not applicable	Recruiting	2026-01	China
Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists NCT07619989 · ClinicalTrials.gov ↗ · Obesity & Overweight	Not applicable	Recruiting	2026-08	China
Probiotics Combined with Enteral Nutrition Reduces Postoperative Infectious Complications in PD NCT06719596 · ClinicalTrials.gov ↗ · Infectious Complications Drug: Bifidobacterium Bifidum	Phase 1/2	Recruiting	2024-05	China
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients NCT06662006 · ClinicalTrials.gov ↗ · Advanced Metastatic Pancreatic Cancer	Phase 2	Recruiting	2024-03	China
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers NCT06561906 · ClinicalTrials.gov ↗ · Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Subjective Cognitive Decline	Observational	Recruiting	2020-09	China
Intravenous Hydromorphone for the Treatment of Acute Pain NCT06949059 · ClinicalTrials.gov ↗ · Acute Chest Pain Drug: Hydromorphone	Phase 1/2	Recruiting	2025-01	China
Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase NCT05661786 · ClinicalTrials.gov ↗ · Chronic Hepatitis b	Observational	Recruiting	2022-12	China
Performances on Cognitive Functions and Brain Function and Follow-up After Different Treatments in Patients With Autonomous Cortisol Secretion: a Single-center, Prospective, Observational Study NCT05357456 · ClinicalTrials.gov ↗ · Autonomous Cortisol Secretion, Adrenal Incidentaloma, Non-functioning Adrenal Adenomas	Observational	Recruiting	2021-10	China
Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors NCT05768464 · ClinicalTrials.gov ↗ · Non-clear Renal Cell Carcinoma Drugs: Axitinib, Toripalimab	Phase 2	Recruiting	2023-02	China
Prophylactic Antibiotics in Preventing Surgical Site Infection After Hepatobiliary Surgery in High-Resistant Settings NCT07620223 · ClinicalTrials.gov ↗ · Hepatobiliary Surgery, Prophylactic Antibiotics Drug: Piperacillin-tazobactam	Not applicable	Recruiting	2026-05	China
Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus NCT06946485 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE) Drug: CHT101	Phase EARLY_PHASE1	Recruiting	2025-04	China
A Multicenter, RAndomlzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With Al-assisted Robotic guidanCe for Hemorrhagic Stroke: Large Basal Ganglia Hemorrhage NCT06484374 · ClinicalTrials.gov ↗ · Hematoma Brain, Large Basal Ganglia Hemorrhage	Not applicable	Recruiting	2025-12	China
Cancer of Esophagogastric Junction: Optimized Sweet Versus Ivor-Lewis NCT06162767 · ClinicalTrials.gov ↗ · Esophagogastric Junction Carcinoma	Not applicable	Recruiting	2023-12	China
Clinical Efficacy and Population Pharmacokinetics of β-lactams in Cirrhotic Patients NCT07612163 · ClinicalTrials.gov ↗ · Bacterial Infections	Observational	Recruiting	2023-12	China
Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation NCT04595864 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Liver Transplantation	Phase 3	Recruiting	2020-11	China
Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History NCT06821685 · ClinicalTrials.gov ↗ · Abortion, Habitual, Infertility Unexplained, Embryo Implantation	Phase 1	Recruiting	2025-02	China
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery NCT06361238 · ClinicalTrials.gov ↗ · Delirium, Postoperative Drug: Liraglutide	Phase 3	Recruiting	2024-11	China
Early Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death NCT06856993 · ClinicalTrials.gov ↗ · Sudden Cardiac Death, Exosome Multiomics, Clinical Prognosis	Observational	Recruiting	2021-12	China
Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer NCT07797816 · ClinicalTrials.gov ↗ · Biliary Tract Cancer Drugs: Fluorouracil, Irinotecan Hydrochloride Liposome, Leucovorin	Phase 2	Recruiting	2026-01	China
Immunotherapy with Autologous Tregs in T1DM NCT06708780 · ClinicalTrials.gov ↗ · Type 1 Diabetes Mellitus	Phase 1	Recruiting	2023-04	China
Diagnostic Value of MRI-targeted Plus Index-lesion-ipsilaterally Systematic Biopsy for Biopsy-naive Men At Risk of Prostate Cancer NCT06584279 · ClinicalTrials.gov ↗ · Prostate Cancer	Observational	Recruiting	2024-10	China
A Prospective Study to Assess the Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS) NCT06987292 · ClinicalTrials.gov ↗ · Psoriasis (PsO), Enthesitis, Psoriasis Arthritis Drug: IL-17i	Observational	Recruiting	2025-05	China
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study) NCT07083154 · ClinicalTrials.gov ↗ · Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes Drug: Mazdutide	Phase 3	Recruiting	2025-09	China
A Study of Metformin to Improve Cardiac Function After LVAD Implantation NCT07666698 · ClinicalTrials.gov ↗ · Heart Failure, Left Ventricular Assist Device Drug: Metformin	Phase 1/2	Recruiting	2026-07	China
China Diabetes Cognitive Dysfunction Early Diagnosis and Intervention Study (China-DECODE Study) NCT06650969 · ClinicalTrials.gov ↗ · Type 2 Diabetes, Subjective Cognitive Decline, Mild Cognitive Impairment	Observational	Recruiting	2016-10	China
CtDNA-guided Maintenance Therapy in Pancreatic Cancer NCT07054879 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Observational	Recruiting	2024-11	China
Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer：a Phase II Study NCT07093866 · ClinicalTrials.gov ↗ · mCRPC Drugs: Abiraterone, Disitamab Vedotin, Prednisone	Phase 2	Recruiting	2025-07	China
Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery NCT07163650 · ClinicalTrials.gov ↗ · Obesity, Weight Loss, Metabolic Surgery Drug: Efsubaglutide Alfa	Phase 4	Recruiting	2025-09	China
Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD NCT07632677 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction-associated Fatty Liver Disease	Observational	Recruiting	2026-05	China
AD-SVF Therapy for Refractory Endometrial Infertility NCT07230600 · ClinicalTrials.gov ↗ · Endometrium; Atrophy, Intrauterine Synechiae	Phase 1	Recruiting	2025-11	China
Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection NCT06968806 · ClinicalTrials.gov ↗ · Aortic Dissection, Inflammation Drug: Ketorolac	Phase 3	Recruiting	2025-10	China
Effect of Colchicine on Perioperative Anti-inflammatory Organ Injury in Cardiac Surgery NCT06118034 · ClinicalTrials.gov ↗ · Inflammatory Response, Cardiac Disease Drug: Colchicine	Phase 3	Recruiting	2024-01	China
Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diquat Concentrations in Human Blood Samples NCT07399574 · ClinicalTrials.gov ↗ · Diquat Poisoning	Observational	Not yet open	2026-09	China
Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer NCT07261592 · ClinicalTrials.gov ↗ · Bladder Cancer, Histone Deacetylase Inhibitor, Entinostat Drug: Entinostat	Phase 1/2	Not yet open	2025-12	China
Influence of Different Prostheses on Postoperative Clinical Function in Total Knee Arthroplasty NCT06617819 · ClinicalTrials.gov ↗ · Knee Arthropathy	Not applicable	Not yet open	2024-09	China
PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer NCT07690878 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 2	Not yet open	2026-07	China
Machine Learning-Guided LIV Selection for Adolescent Idiopathic Scoliosis NCT07723053 · ClinicalTrials.gov ↗ · Adolescent Idiopathic Scoliosis, Lenke Type 1 Adolescent Idiopathic Scoliosis, Lenke Type 5 Adolescent Idiopathic Scoliosis	Not applicable	Not yet open	2026-07	China
Evaluation of an Artificial Intelligence Model for the Prediction of Human Blastocyst Ploidy Without Invasive Procedures NCT06762704 · ClinicalTrials.gov ↗ · The Focus is to Validate the Accuracy of a Non-invasive Artificial Intelligence Model for the Prediction of the Human Blastocyst Ploidy, Preimplantation Genetic Testing (PGT)	Observational	Not yet open	2025-02	China
AI-Based Ultrasound Prediction Model for Intracranial Pressure and Prognosis in Lung Cancer Patients With Leptomeningeal Metastasis: A Dual-Center Study NCT07005791 · ClinicalTrials.gov ↗ · Lung Cancer (NSCLC), Leptomeningeal Metastasis, Intracranial Pressure	Observational	Not yet open	2025-07	China
SNC116 Therapy for Refractory Systemic Lupus Erythematosus NCT07748156 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus Drug: SNC116	Phase EARLY_PHASE1	Not yet open	2026-10	China
Modified Water Vapor Thermal Therapy in Management of Patients With Large-volume Benign Prostatic Hyperplasia NCT06596590 · ClinicalTrials.gov ↗ · Benign Prostatic Hyperplasia	Not applicable	Not yet open	2024-09	China
Intraoperative Ultrasound Assessment of Coronary Artery and Bypass Graft Blood Flow During CABG NCT07700524 · ClinicalTrials.gov ↗ · Coronary Artery Disease	Observational	Not yet open	2027-01	China
Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis NCT07642544 · ClinicalTrials.gov ↗ · Psoriasis, Psoriasis (PsO)	Observational	Not yet open	2026-06	China
The Safety and Efficiency of a Single Dose of CARC-101C in Patients With Autoimmune Type 1 Diabetes Mellitus NCT06546436 · ClinicalTrials.gov ↗ · Autoimmune Type 1 Diabetes Mellitus(T1DM)	Phase EARLY_PHASE1	Not yet open	2024-08	China
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma NCT07314372 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult Drugs: Apatinib, Camrelizumab, Camrelizumab and apatinib	Phase 2	Not yet open	2026-02	China
177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial NCT07677566 · ClinicalTrials.gov ↗ · Prostate Cancer, Prostate Cancer Patients Drugs: Darolutamide, Pluvicto	Phase 4	Not yet open	2026-07	China
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study) NCT05778097 · ClinicalTrials.gov ↗ · Prostate Cancer, Biochemical Recurrence, High Risk Drug: Apalutamide Tab	Phase 2	Not yet open	2023-04	China
A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma NCT07741617 · ClinicalTrials.gov ↗ · Urologic Neoplasms Drugs: Iparomlimab and Tuvonralimab, Lenvatinib	Phase 2	Not yet open	2026-08	China
Effects of Different Exercises on Intrahepatic Lipid in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease NCT06994871 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-Associated Steatotic Liver Disease	Not applicable	By invitation	2025-03	China
CHT105 for the Treatment of Refractory Lupus Nephritis NCT07517536 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus, Lupus Nephritis Drug: CHT105	Not applicable	By invitation	2026-04	China
The Diagnostic Value of Shear Wave Elastography and Viscosity Imaging Techniques in Diabetic Peripheral Neuropathy NCT06773793 · ClinicalTrials.gov ↗ · Diabetic Peripheral Neuropathy (DPN)	Observational	By invitation	2024-04	China
Clinical Classification and Imaging Markers in Patients of Obesity NCT06649071 · ClinicalTrials.gov ↗ · Obesity, fMRI, Clinical Classification	Observational	By invitation	2024-10	China
Development of Obesity and Bariatric Surgery NCT03296605 · ClinicalTrials.gov ↗ · Obesity	Observational	By invitation	2017-03	China
Exploratory Clinical Study on Memory NK Cell Therapy for Advanced Metastatic Solid Tumors NCT07274449 · ClinicalTrials.gov ↗ · Advanced Solid Cancers	Phase 1/2	Active, closed	2025-05	China
Therapeutic Effect of Stem Cell Eye Drops on Dry Eye Disease NCT05784519 · ClinicalTrials.gov ↗ · Mesenchymal Stem Cell, Dry Eye Syndromes	Phase EARLY_PHASE1	Active, closed	2023-09	China
Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease NCT07274644 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-Associated Steatotic Liver Disease, Diabetes Mellitus Type 2 Drug: IGlarLixi	Phase 4	Active, closed	2025-03	China
Electro-acupuncture for SCD With Depression NCT07350226 · ClinicalTrials.gov ↗ · Subjective Cognitive Decline (SCD), Depression Disorder	Not applicable	Active, closed	2025-10	China
Efficacy and Safety of a Novel ERCP Robot in the Treatment of Common Bile Duct Stone NCT07368335 · ClinicalTrials.gov ↗ · ERCP, Robot Surgery, Common Bile Duct Stone	Not applicable	Active, closed	2025-12	China
Prediction of Detoxification Effect of Fat Emulsion Based on Drug Diffusion Law NCT06926439 · ClinicalTrials.gov ↗ · Poisoning, Toxicokinetics, Lipid Emulsion	Observational	Active, closed	2024-06	China
Risk Stratification and Heterogeneity for Organ Damage in Acute Diquat Poisoning NCT06798142 · ClinicalTrials.gov ↗ · Toxic Encephalopathy, Diquat Poisoning	Observational	Active, closed	2022-02	China
Effects of Extracorporeal Treatment in Patients With Acute Poisoning NCT06798129 · ClinicalTrials.gov ↗ · Poisoning, Extracorporeal Treatment	Observational	Active, closed	2015-01	China
Observing the Real-world Non-interventional Study of Abiraterone Acetate Tablets (II) in Treating Chinese Patients With Metastatic Prostate Cancer NCT07721532 · ClinicalTrials.gov ↗ · Diagnosed With Metastatic Prostate Cancer Drug: Abiraterone acetate	Observational	Active, closed	2025-01	China
Evaluate the Efficacy and Safety of SASI Compared with RYGB in the Treatment of Obesity and Related Metabolic Diseases NCT06598267 · ClinicalTrials.gov ↗ · Bariatric Surgery	Not applicable	Active, closed	2024-09	China
Posterior Minimally Invasive Surgery for Treating Paralytic Scoliosis With Pelvic Obliquity in Children Following Spinal Cord Injury NCT07594574 · ClinicalTrials.gov ↗ · Paralytic Scoliosis, Pelvic Obliquity, Spinal Cord Injury	Not applicable	Active, closed	2024-08	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials

49 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 9 more in the trial list above.

Conditions in The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials

131 conditions

Prostate Cancer6 Obesity4 Pancreatic Cancer4Biochemical Recurrence3Type 2 Diabetes3 Mild Cognitive Impairment3 Gastric Cancer2 Type 2 Diabetes Mellitus (T2DM)2Diquat Poisoning2Chronic Hepatitis b2 Metabolic Dysfunction-Associated Steatotic Liver Disease2 Systemic Lupus Erythematosus2 Biliary Tract Cancer2 Obesity & Overweight2Subjective Cognitive Decline (SCD)2Bladder Cancer2 Type 1 Diabetes Mellitus2Subjective Cognitive Decline2Poisoning2Psoriasis (PsO)2Brain Function1Metabolomics1Feeding Behavior1Colorectal Cancer1

By trial register

Register	Trials	Recruiting
Clinical trials in China	90	58

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Prostate Cancer

Sponsor	Trials
University Health Network, Toronto	13
Peking University First Hospital	12
Sunnybrook Health Sciences Centre	10
CHU de Quebec-Universite Laval	8
Sir Mortimer B. Davis - Jewish General Hospital	7
Jiangsu HengRui Medicine	6
British Columbia Cancer Agency	5
European Organisation for Research and Treatment of Cancer - EORTC	5
IRCCS San Raffaele	5
Universitaire Ziekenhuizen KU Leuven	5

Sponsors with the most current trials registered for this condition.

Questions about The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials

How many clinical trials does The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School sponsor?

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School is the lead sponsor of 90 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials recruiting?

Yes. 58 of its 90 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School testing?

Its current trials name 49 drugs and biologicals as interventions. The most frequent are Rezvilutamide (4), Abiraterone acetate (2), Fluorouracil (2), Irinotecan Hydrochloride Liposome (2) and Leucovorin (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School clinical trials